Data Collective IV GP LLC's Q2 2022 13F: no position changes
Form 13F-HR for the quarter ended Jun 30, 2022 · filed Nov 14, 2022 · 5 reported positions · accession 0001104659-22-118010
What changed this quarter
No equity positions were opened, closed, increased or reduced in this filing.
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
No changes in the top 10 this quarter
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Recursion Pharmaceuticals, Inc. (RXRX) | 9.0% | 39.9% | |
| 2 | Embark Trucks, Inc. (EMBK) | 79.7% | 26.6% | |
| 3 | Evolv Technologies (EVLV) | 6.0% | 23.3% | |
| 4 | Rocket Lab USA, Inc. (RKLB) | 5.0% | 9.2% | |
| 5 | Mind Medicine (MindMed) Inc. (MNMD) | 0.4% | 1.0% |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).